Tags

Type your tag names separated by a space and hit enter

Review of dengue virus and the development of a vaccine.
Biotechnol Adv. 2011 Mar-Apr; 29(2):239-47.BA

Abstract

Dengue viral infection has become an increasing global health concern with over two-fifths of the world's population at risk of infection. It is the most rapidly spreading vector borne disease, attributed to changing demographics, urbanization, environment, and global travel. It continues to be a threat in over 100 tropical and sub-tropical countries, affecting predominantly children. Dengue also carries a hefty financial burden on the health care systems in affected areas, as those infected seek care for their symptoms. The search for a suitable vaccine for dengue has been ongoing for the last sixty years, yet any effective treatment or vaccine remains elusive. A vaccine must be protective for all four serotypes of dengue and be cost-effective. Many approaches to developing candidate vaccines have been employed. The candidates include live attenuated tetravalent vaccines, chimeric tetravalent vaccines based on attenuated dengue virus or Yellow Fever 17D, and recombinant DNA vaccines based on flavivirus and non-flavivirus vectors. This review outlines the challenges involved in dengue vaccine development and presents the current stages of proposed vaccine candidate development.

Authors+Show Affiliations

Department of Microbiology, University of Manitoba, Winnipeg, Manitoba, Canada.No affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

21146601

Citation

Murrell, Sarah, et al. "Review of Dengue Virus and the Development of a Vaccine." Biotechnology Advances, vol. 29, no. 2, 2011, pp. 239-47.
Murrell S, Wu SC, Butler M. Review of dengue virus and the development of a vaccine. Biotechnol Adv. 2011;29(2):239-47.
Murrell, S., Wu, S. C., & Butler, M. (2011). Review of dengue virus and the development of a vaccine. Biotechnology Advances, 29(2), 239-47. https://doi.org/10.1016/j.biotechadv.2010.11.008
Murrell S, Wu SC, Butler M. Review of Dengue Virus and the Development of a Vaccine. Biotechnol Adv. 2011 Mar-Apr;29(2):239-47. PubMed PMID: 21146601.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Review of dengue virus and the development of a vaccine. AU - Murrell,Sarah, AU - Wu,Suh-Chin, AU - Butler,Michael, Y1 - 2010/12/10/ PY - 2010/08/02/received PY - 2010/11/28/revised PY - 2010/11/29/accepted PY - 2010/12/15/entrez PY - 2010/12/15/pubmed PY - 2011/5/13/medline SP - 239 EP - 47 JF - Biotechnology advances JO - Biotechnol Adv VL - 29 IS - 2 N2 - Dengue viral infection has become an increasing global health concern with over two-fifths of the world's population at risk of infection. It is the most rapidly spreading vector borne disease, attributed to changing demographics, urbanization, environment, and global travel. It continues to be a threat in over 100 tropical and sub-tropical countries, affecting predominantly children. Dengue also carries a hefty financial burden on the health care systems in affected areas, as those infected seek care for their symptoms. The search for a suitable vaccine for dengue has been ongoing for the last sixty years, yet any effective treatment or vaccine remains elusive. A vaccine must be protective for all four serotypes of dengue and be cost-effective. Many approaches to developing candidate vaccines have been employed. The candidates include live attenuated tetravalent vaccines, chimeric tetravalent vaccines based on attenuated dengue virus or Yellow Fever 17D, and recombinant DNA vaccines based on flavivirus and non-flavivirus vectors. This review outlines the challenges involved in dengue vaccine development and presents the current stages of proposed vaccine candidate development. SN - 1873-1899 UR - https://www.unboundmedicine.com/medline/citation/21146601/Review_of_dengue_virus_and_the_development_of_a_vaccine_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0734-9750(10)00165-5 DB - PRIME DP - Unbound Medicine ER -